Siemens to sell off nonmedical divisions

Article

German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the company’s

German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the company’s Medical Engineering Group, which continues to post an encouraging turnaround, according to the company.

Siemens AG president and CEO Heinrich von Pierer has been restructuring the company for the past year, shedding underperforming business units. This month’s news represents the most radical move yet in his campaign to reshape Siemens, however.

The bulk of Von Pierer’s plans involve the company’s Components group, which consists of operations in semiconductors, passive components and electron tubes, and electromechanical components. The semiconductors business will be spun off as an independent company, while Siemens is still examining its options for the passive components and electron tubes business. Siemens is also seeking a partner for the electromechanical components business. The businesses to be divested have annual sales of about $10.2 billion.

Siemens reported that operations in its Medical Engineering Group have improved significantly since the unit reported an operating loss last year. Medical Engineering reported annual sales of $4.5 billion, up 11% compared with sales from continuing operations last year. The group’s operating profit before taxes was $100.3 million, compared with a loss of $102.1 million the year before.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.